OPRXHIGH SIGNALFINANCIAL10-K

OptimizeRx achieved a dramatic operational turnaround, swinging from a $13.7M operating loss to $11.7M operating profit while significantly improving cash generation.

This represents a fundamental transformation in the company's financial performance, demonstrating management's ability to achieve profitability while maintaining growth. The shift from cash burn to strong cash generation provides greater financial flexibility and reduces dilution risk for shareholders.

Comparing 2026-03-12 vs 2025-03-20View on EDGAR →
FINANCIAL ANALYSIS

OptimizeRx delivered exceptional financial improvements across all key metrics, with operating cash flow surging 283% to $18.7M and the company achieving profitability with $11.7M in operating income versus a $13.7M loss previously. Revenue growth of 24% to $73.6M in gross profit was efficiently converted to bottom-line results despite higher SG&A expenses, while the balance sheet strengthened significantly with 75% higher cash balances and 23% debt reduction. This comprehensive financial turnaround signals a maturing business model with improving operational leverage and enhanced financial stability.

FINANCIAL STATEMENT CHANGES
Operating Cash Flow
Cash Flow
+282.8%
$4.9M→$18.7M

Operating cash flow surged 282.8% — exceptional cash generation, highest quality earnings signal.

Operating Income
P&L
+185.3%
-$13.7M→$11.7M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Net Income
P&L
+125.5%
-$20.1M→$5.1M

Net income grew 125.5% — bottom-line growth signals improving overall business health.

Cash & Equivalents
Balance Sheet
+74.6%
$13.4M→$23.4M

Cash position surged 74.6% — strong cash generation or capital raise providing significant financial cushion.

Share Buybacks
Cash Flow
-62.4%
$20.0M→$7.5M

Buyback activity reduced 62.4% — capital being redeployed elsewhere or cash conservation underway.

Capital Expenditure
Cash Flow
-48.2%
$112K→$58K

Capex reduced 48.2% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Gross Profit
P&L
+23.9%
$59.4M→$73.6M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Total Debt
Balance Sheet
-23.3%
$34.3M→$26.3M

Debt reduced 23.3% — deleveraging strengthens balance sheet and reduces financial risk.

SG&A Expense
P&L
+20.9%
$27.7M→$33.5M

SG&A increased modestly — likely reflects growth-related hiring or sales expansion investment.

Current Assets
Balance Sheet
+19.9%
$54.0M→$64.7M

Current assets grew 19.9% — improving short-term liquidity or inventory/receivables build.

LANGUAGE CHANGES
NEW — 2026-03-12
PRIOR — 2025-03-20
ADDED
Unless otherwise specified or the context otherwise requires, when used in this Annual Report on Form 10-K, the terms we, our, us, OptimizeRx, or the Company refer to OptimizeRx Corporation and its subsidiaries on a consolidated basis.
We are dependent on a concentrated group of customers, and the loss of one or more of any of the pharmaceutical brands that purchase our solutions could cause our revenue to decline.
We expect to face increasing competition in the markets of our solutions.
If our customers drug prices are reduced as a result of MFN pricing initiatives or other similar regulations, our business could be adversely affected by our customers reducing their marketing and advertising spend.
Business General OptimizeRx is a leading digital healthcare technology company that is redefining how life sciences brands engage with, market their services and products to, and support patients and healthcare providers.
+7 more — sign up free →
REMOVED
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C.
Form 10-K Summary 35 i FORWARD LOOKING STATEMENT This Annual Report on Form 10-K contains statements that relate to future events and expectations and, as such, constitute forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995.
Unless otherwise specified or the context otherwise requires, when used in this Annual Report on Form 10-K, the terms we, our, us, OptimizeRx, or the Company refer to OptimizeRx Corporation and its subsidiaries.
If we are unable to maintain our contracts with electronic prescription platforms and electronic health record systems, our business will suffer.
The markets in which we operate are competitive, continually evolving and, in some cases, subject to rapid change.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →